A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Trial Profile

A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Ridinilazole (Primary) ; Vancomycin
  • Indications Clostridium infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CoDIFy
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 01 Jul 2017 Results published in The Lancet Infectious Diseases
    • 02 May 2017 Results from this trial have been published in The Lancet Infectious Diseases, according to a Summit Therapeutics media release.
    • 02 May 2017 Results published in a Summit Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top